Meeting
2014 ASCO Annual Meeting
A marker-driven phase II trial of neoadjuvant chemotherapy in locally advanced colon cancer.
Authors
Anders Kristian Moeller Jakobsen
Department of Oncology, Vejle Hospital, Vejle, Denmark
Anders Kristian Moeller Jakobsen , Fahimeh Andersen , Anders Fischer , Lars Henrik Jensen , Jens Christian Riis Joergensen , Ole Larsen , Jan Lindebjerg , John Ploeen , Soeren Rafael Rafaelsen , Jesper Vilandt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01918527
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3621)
DOI
10.1200/jco.2014.32.15_suppl.3621
Abstract #
3621
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Perioperative chemotherapy using FOLFOX with panitumumab for locally advanced rectal cancer: Phase II trial.
First Author: Mitsuyoshi Ota
Poster
2011 ASCO Annual Meeting
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
First Author: I. Chau
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of CAPOXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSGO).
First Author: Yoshinori Kagawa
Poster
2015 Gastrointestinal Cancers Symposium
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).
First Author: Daniel Helbling